This acquisition complements our growth ambitions for South Africa and fortifies our investment in the country.
Acino and Aspen have signed an agreement for Acino to acquire six of its prescription medicines in South Africa.
Acino will be ADQ’s largest acquisition in its healthcare and pharma portfolio to date.
Acino’s philosophy of diversity resonates with South Africa’s philosophy of equal opportunity, and we are extremely proud to have attained Level 1 B-BBEE status.
We are currently all facing a time that we have never experienced before as individuals or as businesses, and all of us have a part to play as we face COVID-19. At Acino, our goal is to ensure the wellbeing of our colleagues and the continued supply of critical medicines to patients around the world.
Acino will acquire approximately 30 products from Takeda’s primary care portfolio in selected countries in the Middle East and Africa, and in Ukraine; subject to conditions.
John Norman, Regional Director English Speaking Africa shares his thoughts on what Acino means for South Africa.
Established in Switzerland since 1836 and with a proven track record of high quality products for many years the deeply rooted high standard quality pledge is reflected in all of Acino’s activities: from the igniting idea to the final product, from technological development to state-of-the-art production, nothing is left to chance.
When you choose Acino, you are choosing quality you can rely on.
Our Mission is to deliver quality pharmaceuticals to promote affordable healthcare.
Growing fast and making an impact for patients in emerging markets.
Who we are, what we stand for and are signposts for what we need to aspire to in our everyday actions.